Trastuzumab Pharmacokinetics Influenced by Extent Human Epidermal Growth Factor Receptor 2-Positive Tumor Load

University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Journal of Clinical Oncology (Impact Factor: 18.43). 05/2010; 28(21):e355-6; author reply e357. DOI: 10.1200/JCO.2010.28.4604
Source: PubMed
Download full-text


Available from: Thijs Oude Munnink, Oct 28, 2015
  • Source
    • "Zr-trastuzumab PET allowed quantification of conjugate uptake in HER2-positive lesions, and it became clear that for some patients with extensive tumor load no HER2 saturation occurred during trastuzumab therapy [21]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent advances in molecular and cellular biology have facilitated the discovery of the key molecular drivers of major diseases. This knowledge raised some optimism in the beginning of this century, yet its impact on disease prevention, diagnosis and targeted intervention remains low. At the same time the pharmaceutical industry is facing the dual challenges of a dwindling drug pipeline and ever increasing cost of drug development. It is against this background that a number of European countries decided to establish EATRIS, the European Advanced Translational Research InfraStructure in Medicine. EATRIS aims for faster and more efficient translation of basic research into innovative products, by providing academia and industry access to the state-of-the-art expertise and highly capital-intensive facilities residing in Europe's top translational research centers and hospitals. To this end, EATRIS formed product groups that provide translational services in the fields of development and supply of (1) molecular imaging and tracing, (2) vaccines, (3) biomarkers, (4) small molecules and (5) advanced therapeutic medicinal products. Herein we describe the background, goals, functions and structure of EATRIS. As an example, it will be described how EATRIS centers involved in imaging and tracing might contribute to more efficient drug development and personalized medicine.
    American Journal of Nuclear Medicine and Molecular Imaging 03/2013; 3(2):166-74. · 3.25 Impact Factor
  • Source
    • "Recently, another study indicated that trastuzumab pharmacokinetics and organ distribution can also be heavily affected by an extensive tumor load [31]. Therefore, a study with a more patient-tailored trastuzumab dosing schedule on the basis of tumor volume in addition to bodyweight should be considered in the future. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Positron emission tomography (PET) imaging with radiolabeled monoclonal antibodies has always been a dynamic area in molecular imaging. With decay half-life (3.3 d) well matched to the circulation half-lives of antibodies (usually on the order of days), (89)Zr has been extensively studied over the last decade. This review article will give a brief overview on (89)Zr isotope production, the radiochemistry generally used for (89)Zr-labeling, and the PET tracers that have been developed using (89)Zr. To date, (89)Zr-based PET imaging has been investigated for a wide variety of cancer-related targets, which include human epidermal growth factor receptor 2, epidermal growth factor receptor, prostate-specific membrane antigen, splice variant v6 of CD44, vascular endothelial growth factor, carbonic anhydrase IX, insulin-like growth factor 1 receptor, among others. With well-developed radiochemistry, commercial availability of chelating agents for (89)Zr labeling, increasingly widely available isotope supply, as well as successful proof-of-principle in pilot human studies, it is expected that PET imaging with (89)Zr-based tracers will be a constantly evolving and highly vibrant field in the near future.
    04/2011; 4(2):131-9. DOI:10.2174/1874471011104020131
  • [Show abstract] [Hide abstract]
    ABSTRACT: The concept of monoclonal antibodies (mAbs) as pharmacotherapeutics was validated in the mid-1980s with the successful clinical development of the fully murine mAb muromonab-CD3 for prevention of acute organ rejection. However, clinical applications of fully murine mAbs are restricted, owing to the high incidence of serious immune-mediated side effects, particularly upon repeated exposure. The rate and severity of immune-mediated toxicities of these agents were significantly attenuated by the development of mouse/human chimeric, fully human, and humanized mAbs. These refinements in molecular structure allowed repeated, long-term administration, where therapeutically warranted, which, in turn, broadened the scope of indications for this class of therapy. Presently, numerous mAbs are approved or are undergoing clinical evaluation for treatment of oncologic and chronic inflammatory diseases. The current experimental development landscape spans respiratory, metabolic, and central nervous system disorders as well as infectious disease. A consequence of the expanding numbers of mAb indications is concomitant administration of these agents with established small molecule pharmacotherapies, which necessitates a comprehensive understanding of mAb-small molecule drug interactions as well as mAb-mAb interactions. Current knowledge indicates that mAbs do not elicit a direct effect on the metabolic/clearance pathways for small molecular therapeutics. However, the immunomodulatory properties of mAbs can indirectly alter clearance of certain small molecule entities through the attenuation of noncatabolic enzymatic pathways.
    Annual Review of Pharmacology 01/2010; 51(1):359-72. DOI:10.1146/annurev-pharmtox-010510-100510 · 18.37 Impact Factor
Show more